Clearside Biomedical, INC 8-K filings

Clearside Biomedical, Inc. secured court approval for its asset sale bidding procedures and designated Health Ocean Limited as the stalking horse bidder, while also filing its initial monthly operating report.

Clearside Biomedical, Inc. has completed its delisting from The Nasdaq Stock Market LLC and transferred trading to the OTC Pink Limited Market following its Chapter 11 bankruptcy filing.

Clearside Biomedical has filed for Chapter 11 bankruptcy and faces delisting from Nasdaq, aiming to sell its assets.

Clearside Biomedical, Inc. announced it has regained compliance with Nasdaq's Minimum Bid Price Requirement, resolving a prior delisting threat.

Clearside Biomedical, Inc. has filed an amendment to its certificate of incorporation to effect a 1-for-15 reverse stock split and reduce its authorized common shares.

Clearside Biomedical, Inc. will implement a 1-for-15 reverse stock split and reduce authorized common shares, effective September 12, 2025.

Clearside Biomedical amended its royalty agreement, receiving an additional $3 million for its SCS Microinjector technology assets and reducing future royalty obligations.

Clearside Biomedical received a Nasdaq delisting notice for failing to meet the minimum market value requirement and previously for its bid price, while stockholders approved a reverse stock split to address compliance.

Clearside Biomedical received a delisting notice from Nasdaq due to its low stock price, while its Board Chairperson resigned.

A biopharmaceutical company is exploring strategic alternatives to enhance shareholder value, implementing a full workforce transition to consulting roles, and pausing internal research and development programs.

Clearside Biomedical, Inc. announced that its stockholders approved an amendment to increase the authorized number of common shares from 200 million to 400 million at its 2025 annual meeting, alongside the election of directors and executive compensation approval.

Clearside Biomedical reports successful FDA meeting regarding CLS-AX and announces Q1 2025 financial results, highlighting increased revenue and reduced net loss.

Clearside Biomedical reports alignment with the FDA on Phase 3 plans for CLS-AX in wet AMD, along with financial results for Q4 and full-year 2024 and a corporate update.

Clearside Biomedical received a notice from Nasdaq regarding non-compliance with minimum bid price requirements, potentially leading to delisting.

Clearside Biomedical has updated its corporate presentation, highlighting positive Phase 2b results for CLS-AX in wet AMD and plans for Phase 3 trials.

Clearside Biomedical announced positive results from its Phase 2b trial of CLS-AX for wet AMD and a commercial licensing agreement for China, highlighting progress in its suprachoroidal drug delivery platform.

Clearside Biomedical's CLS-AX demonstrated positive topline results in a Phase 2b trial for wet AMD, showing stable visual acuity and reduced injection frequency, paving the way for Phase 3 development.

Clearside Biomedical announced its second quarter 2024 financial results, highlighting the progress of its Phase 2b ODYSSEY trial and other corporate developments.

Clearside Biomedical hosted a webinar emphasizing the versatility and potential of its suprachoroidal drug delivery platform, including updates on its clinical programs.

Clearside Biomedical successfully held its 2024 annual meeting, electing three directors and ratifying its independent auditor.

Clearside Biomedical announced its first quarter 2024 financial results and provided a corporate update, highlighting progress in its lead clinical program and key management additions.

Clearside Biomedical has appointed Anthony S. Gibney, a seasoned biotech executive, to its Board of Directors, effective April 15, 2024.

Clearside Biomedical announced its fourth quarter and full year 2023 financial results, highlighting progress in its clinical programs and a strengthened financial position.

Clearside Biomedical has announced a registered direct offering to raise approximately $15 million through the sale of common stock and warrants.

Clearside Biomedical has amended its license agreement with Emory University and Georgia Tech Research Corporation, reducing the sublicense percentage and adjusting annual maintenance fees.